Appointment dossier — Peritoneal Sarcoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Peritoneal Sarcoma
- Methotrexate — Animal evidence · 1 positive · PMID 16052545
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT06753136 — Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype (Italy)
- NCT05503797 · Phase 2 — A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations (United States)
- NCT05579366 · Phase 1 / Phase 2 — Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) (United States)
- NCT06840886 · Phase 1 — A Study of PHST001 in Advanced Solid Tumors (United States)
- NCT07487168 · Phase 1 — Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors (United States)
- NCT06912152 · Phase 1 — MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors (China)
- NCT04684459 · Early Phase 1 — Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors (China)
- NCT07218809 · Phase 3 — AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (United States)
- NCT05009082 · Phase 3 — Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer (Germany)
- NCT05538091 · Phase 2 — Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (United States)
- NCT03564340 · Phase 1 / Phase 2 — Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers (United States)
- NCT07023484 · Phase 2 — Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer (China)
- NCT07133490 · Phase 2 — INTERACT Stomach-II (Netherlands)
- NCT04107077 · Phase 2 — Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer (United States)
- NCT07489287 · Phase 1 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer (United States)
- NCT06483048 · Phase 1 — MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer (United States)
- NCT05477927 · Phase 1 — Dual-targeting VEGFR1 and PD-L1 CAR-T for Pleural, Peritoneal, or Leptomeningeal Metastases (China)
- NCT02012699 — Integrated Cancer Repository for Cancer Research (United States)
Most-relevant first: trials that name Peritoneal Sarcoma, then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT06753136), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?